In 2022, over 9.1 thousand people in England were diagnosed with esophageal cancer. The most affected age group was among those aged 75 to 79 years with 1,152 diagnoses in men of this age and 488 cases for women. The esophagus is also known as the gullet and is the tube that carries food to the stomach. Lifestyles which increase risk of developing esophageal cancer Certain harmful behaviors can increase the risk of a person developing esophageal cancer such as smoking or drinking excessive amounts of alcohol according to the NHS. As of 2022, 14 percent of men in England were regular smokers as well as 11 percent of women. Additionally, a study from 2022 found that many age groups, men in particular, exceed the recommended units of alcohol consumption of 1 units on an average week. Another aspect is diet Having a healthy diet is also an extra way to abet esophageal cancer, in particular the consumption of fruit and vegetables. The recommend advice is to consume at least five portions of fruit and vegetables per day. In 2018/19, among adults in England, 30 percent of women and 25 percent of men declared that they consume five portions or more per day. On the contrary, nine and seven percent of men and women respectively in England reported consuming no fruit or vegetables on a typical day.

Data on the age-specific incidence of esophageal cancer are lacking. Our aim was to investigate the age-stratified incidence, treatment, and survival trends of esophageal cancer in the Netherlands, with a focus on adults

ObjectiveTo elucidate the historical trends, underlying causes and future projections of esophageal cancer incidence in Hong Kong.MethodsUtilizing the Age-Period-Cohort (APC) model, we analyzed data from the Hong Kong Cancer Registry (1992–2021) and United Nations World Population Prospects 2022 Revision. Age-standardized incidence rates were computed, and APC models evaluated age, period, and cohort effects. Bayesian APC modeling, coupled with decomposition analysis, projected future trends and identified factors influencing incidence.ResultsBetween 1992 and 2021, both crude and age-standardized incidence rates of esophageal cancer witnessed significant declines. Net drifts exhibited pronounced downward trends for both sexes, with local drift diminishing across all age groups. Period and cohort rate ratios displayed a consistent monotonic decline for both sexes. Projections indicate a continued decline in esophageal cancer incidence. Population decomposition analysis revealed that epidemiological changes offset the increase in esophageal cancer cases due to population growth and aging.ConclusionThe declining trend of esophageal cancer in Hong Kong is influenced by a combination of age, period, and cohort. Sustaining and enhancing these positive trends requires continuous efforts in public health interventions.

This statistic shows the death rate of esophagus cancer in the United States from 1999 to 2021. The maximum rate in the given period was *** per every 100,000 age-adjusted population, while the minimum rate stood at ***.

Esophageal Cancer Market is set to reach USD 3,232.05 Million by 2032 with CAGR of 8.2% during the forecast period (2025-2032) from value of USD 1,730.43 Million in 2024. Additionally, value is estimated to grow by value of USD 1,865.62 Million in 2025.

The global esophageal cancer market size was worth around USD 14.31 billion in 2025 and is set to register a CAGR of more than 7.5% from 2026 to 2035, driven by acceptance for treatments and prevention.

BackgroundEsophageal cancer is a global health concern. Regularly updated data about the burden of esophageal cancer are essential for formulating specific public policies. We aimed to estimate the global, regional, and national burden and trends of esophageal cancer and its attributable risk factors from 1990 to 2019, by age, sex and socio-demographic index (SDI).MethodsData about the incidence, death, disability-adjusted life-years (DALYs), and age-standardized rates were collected from Global Burden of Disease study 2019. Estimated annual percentage changes were used to quantify the temporal trends of age-standardized rates. Moreover, the risk factors attributable to esophageal cancer deaths were also presented.ResultsThere were 534,563 incident cases and 498,067 deaths in 2019, contributing to 11,666,017 DALYs. The absolute numbers of incidence, death, and DALYs had increased from 1990 to 2019, contrasting with declined changes in their corresponding age-standardized rates. The burden of esophageal cancer varied across different regions and countries, and the age-standardized rates were negative with SDI. Almost half of the esophageal cancer was concentrated in China. Males accounted for most of the burden of esophageal cancer, and the onset age tended to be older. The death of esophageal cancer was primarily attributable to smoking, followed by alcohol use, high body mass index, diet low in fruits and diet low in vegetables.ConclusionThe burden of esophageal cancer was heterogeneous across regions and countries by sex, age, and SDI, providing information for governments that may help to formulate more targeted policies.

Medical Molecular Testing for Esophageal Cancer Market Outlook

The global medical molecular testing for esophageal cancer market is projected to reach USD 1.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.8% from 2024 to 2032. The rising prevalence of esophageal cancer worldwide and advances in molecular diagnostic technologies are major growth factors driving this market.

The increasing incidence of esophageal cancer globally is one of the primary growth drivers for the medical molecular testing market. According to the World Health Organization (WHO), esophageal cancer is the eighth most common cancer worldwide, with approximately 572,000 new cases and 508,000 deaths reported in 2018. This alarming rate of incidence and mortality emphasizes the need for early and accurate diagnosis, thereby boosting the demand for molecular testing. Such tests offer superior sensitivity and specificity compared to traditional diagnostic methods, making them a preferred choice for healthcare professionals.

Technological advancements in molecular diagnostic techniques are significantly contributing to market growth. Innovations such as next-generation sequencing (NGS), polymerase chain reaction (PCR), and fluorescence in situ hybridization (FISH) have revolutionized cancer diagnostics. These techniques enable the identification of genetic mutations and molecular markers that are critical for early detection and personalized treatment of esophageal cancer. The integration of artificial intelligence (AI) and machine learning (ML) in molecular diagnostics is further enhancing the accuracy and efficiency of these tests, thereby driving market growth.

Government initiatives and funding for cancer research are also playing a crucial role in the expansion of the medical molecular testing market. Various governments and non-profit organizations are investing heavily in cancer research to develop advanced diagnostic and therapeutic solutions. For instance, the National Cancer Institute (NCI) in the United States allocates significant funds for cancer research, including esophageal cancer. Such initiatives are expected to propel the development and adoption of molecular testing technologies, thereby fostering market growth.

In the realm of hereditary colorectal cancer, molecular diagnosis plays a pivotal role in identifying individuals at risk and guiding preventive measures. The Molecular Diagnosis of Hereditary Colorectal Cancer involves analyzing specific genetic mutations that predispose individuals to this type of cancer. Techniques such as next-generation sequencing and multiplex ligation-dependent probe amplification are employed to detect mutations in genes like APC, MLH1, and MSH2. This diagnostic approach not only aids in early detection but also informs family members about their potential risk, enabling proactive health management. As molecular diagnostics continue to evolve, they offer hope for more personalized and effective interventions in hereditary colorectal cancer.

Regionally, North America holds the largest market share due to the high prevalence of esophageal cancer, well-established healthcare infrastructure, and robust research and development activities. However, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period. Factors such as increasing healthcare expenditure, rising awareness about early cancer diagnosis, and a growing patient population are driving the market in this region.

Test Type Analysis

The medical molecular testing for esophageal cancer market is segmented by test type into PCR, NGS, FISH, IHC, and others. Each of these test types offers unique advantages and is utilized based on specific diagnostic requirements. PCR, or polymerase chain reaction, is one of the most widely used techniques due to its high sensitivity and ability to amplify small amounts of DNA. This makes it an invaluable tool for detecting genetic mutations associated with esophageal cancer. PCR's widespread adoption in clinical and research settings is expected to continue driving market growth in this segment.

Next-generation sequencing (NGS) is another crucial segment within the test type category. NGS allows for comprehensive analysis of genetic alterations and provides detailed insights into the molecular landscape of esophageal cancer. This technology is particularly beneficial for identifying novel geneti

Esophageal Cancer Therapeutics Market Outlook

According to our latest research, the global esophageal cancer therapeutics market size reached USD 1.62 billion in 2024, driven by advancements in targeted therapies and rising incidence rates worldwide. The market is projected to grow at a robust CAGR of 8.9% from 2025 to 2033, reaching an estimated USD 3.47 billion by 2033. This significant growth trajectory is primarily attributed to increasing awareness, early diagnosis, and the introduction of novel therapeutic modalities. The expanding adoption of immunotherapy and targeted agents, combined with enhanced healthcare infrastructure in emerging economies, continues to bolster market expansion, as per our most recent analysis.

The growth of the esophageal cancer therapeutics market is primarily fueled by the rising global prevalence of esophageal cancer, which remains one of the most lethal malignancies due to its late diagnosis and aggressive progression. The aging population, coupled with lifestyle risk factors such as tobacco use, excessive alcohol consumption, and dietary habits, has contributed to a higher incidence rate globally. Furthermore, improvements in diagnostic techniques, including endoscopy and molecular profiling, have enabled earlier detection, thereby increasing the number of patients eligible for advanced therapeutic interventions. This shift towards early intervention is translating into higher demand for both established and novel esophageal cancer therapeutics.

Another key growth driver is the rapid advancement in therapeutic approaches, particularly the integration of immunotherapy and targeted therapies into standard treatment regimens. The introduction of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, and HER2-targeted therapies has significantly improved clinical outcomes for patients with advanced or metastatic esophageal cancer. Pharmaceutical companies are actively investing in research and development, leading to a robust pipeline of novel agents that promise to extend survival and enhance quality of life. The increasing number of regulatory approvals for new drug classes and combination therapies is also accelerating market growth, as patients and clinicians seek more effective and less toxic treatment options.

Additionally, the expansion of healthcare infrastructure and improved access to cancer care in emerging markets are contributing substantially to the growth of the esophageal cancer therapeutics market. Governments and private organizations are investing in cancer awareness campaigns, screening programs, and the establishment of specialized oncology centers, particularly in Asia Pacific and Latin America. These initiatives have led to higher diagnosis rates and increased patient access to innovative therapeutics. Furthermore, collaborations between international pharmaceutical companies and local healthcare providers are facilitating the introduction of advanced treatment options in regions previously underserved, thereby expanding the global market footprint.

Regionally, North America continues to dominate the esophageal cancer therapeutics market due to its advanced healthcare infrastructure, high adoption of novel therapies, and strong presence of leading pharmaceutical companies. Europe follows closely, benefiting from comprehensive cancer screening programs and robust research funding. However, the Asia Pacific region is emerging as the fastest-growing market, driven by a large patient pool, increasing healthcare expenditure, and rapid adoption of modern therapeutic modalities. Latin America and the Middle East & Africa are also witnessing gradual market expansion, supported by rising awareness and government-led cancer control initiatives.

Therapy Type Analysis

The therapy type segment of the esophageal cancer therapeutics market encompasses chemotherapy, immunotherapy, targeted therapy, radiation therapy, surgery, and other emerging modalities. Chemotherapy remains a cornerstone of treatment, particularly for advanced-stage disease, due to its established efficacy and widespread availability. However, the landscape is rapidly evolving, with immunotherapy and targeted therapy gaining significant traction. Immunotherapy, especially immune checkpoint inhibitors, has demonstrated promising results in clinical trials, leading to their approval for use in specific patient populations. These advancements are reshaping treatment paradigms, with combinat

Esophageal Cancer Diagnostics Market Outlook

According to our latest research, the global esophageal cancer diagnostics market size in 2024 stands at USD 2.65 billion, showing robust growth momentum. The market is projected to expand at a CAGR of 7.8% during the forecast period, reaching approximately USD 5.26 billion by 2033. This growth is propelled by increasing incidence rates of esophageal cancer worldwide, rapid advancements in diagnostic technologies, and a surge in awareness and screening initiatives across both developed and emerging regions. As per the latest research, the esophageal cancer diagnostics market is witnessing a paradigm shift towards early detection and precision medicine, which are significantly enhancing patient outcomes and driving market expansion.

One of the primary growth factors for the esophageal cancer diagnostics market is the rising prevalence of esophageal cancer, particularly in regions with high-risk populations. Lifestyle factors such as tobacco use, excessive alcohol consumption, and dietary habits have been linked to the increased incidence of this malignancy. Consequently, healthcare systems are under mounting pressure to develop and implement effective screening and diagnostic protocols. Governments and health organizations are responding by launching awareness campaigns and subsidizing screening programs, especially in Asia Pacific and parts of Europe where the disease burden is notably high. These initiatives are resulting in earlier detection rates, which, in turn, are boosting demand for advanced diagnostic solutions.

Another significant driver is the continuous technological innovation in diagnostic modalities. The integration of novel imaging techniques, molecular diagnostics, and artificial intelligence-driven analytics is transforming the landscape of esophageal cancer detection. For instance, advancements in endoscopic imaging, such as narrow-band imaging and confocal laser endomicroscopy, are enabling clinicians to identify pre-cancerous lesions with higher accuracy. Furthermore, the adoption of next-generation sequencing and liquid biopsy technologies is facilitating the identification of genetic and molecular markers associated with esophageal cancer. These technological breakthroughs are not only improving diagnostic accuracy but also supporting the development of targeted therapies, thereby fueling overall market growth.

The market is further bolstered by increasing investments from both public and private sectors in cancer research and diagnostics infrastructure. Major healthcare players are collaborating with academic institutions and biotechnology firms to accelerate the development of innovative diagnostic tools. Additionally, the growing trend of personalized medicine is encouraging the adoption of molecular and genetic testing as standard procedures in esophageal cancer diagnostics. The expansion of healthcare infrastructure in emerging economies, coupled with favorable regulatory policies and reimbursement frameworks, is also playing a pivotal role in market expansion. Collectively, these factors are creating a conducive environment for sustained growth in the esophageal cancer diagnostics market over the next decade.

From a regional perspective, North America currently dominates the esophageal cancer diagnostics market, owing to its advanced healthcare infrastructure, high awareness levels, and significant investments in research and development. However, the Asia Pacific region is expected to register the fastest growth during the forecast period, driven by a large patient pool, rising healthcare expenditure, and increasing government initiatives to combat cancer. Europe remains a significant market, benefiting from robust healthcare systems and early adoption of cutting-edge diagnostic technologies. Meanwhile, Latin America and the Middle East & Africa are gradually emerging as promising markets, supported by improving access to healthcare services and growing emphasis on early cancer detection.

Diagnostic Type Analysis

The esophageal cancer diagnostics market is segmented by diagnostic type into imaging tests, endoscopic procedures, biopsy, molecular diagnostics, blood tests, and others. Imaging tests, including CT scans, PET scans, and barium swallow X-rays, play a crucial role in the initial assessment and staging of esophageal cancer. The demand for imaging tests is consistently high due to their non-invasive nature and ability to p

The GLOBOCAN database revealed that there were 544,100 esophageal cancer deaths and 604,100 new cases worldwide in 2020, translating to age-standardized incidence and mortality rates of 6.3 and 5.6 per 100,000, respectively. Interestingly, men account for about 70% of instances, and there is a significant gender disparity in frequency worldwide, with men being impacted two to five times more frequently than women.

The Molecular Diagnosis in Esophageal Cancer market is rapidly evolving, driven by the increasing prevalence of esophageal cancer and the demand for precise and personalized treatment options. Molecular diagnosis plays a pivotal role in identifying specific genetic mutations and molecular markers associated with eso

• The global industry was valued at US$ 2.2 Bn in 2023
• It is expected to grow at a CAGR of 6.7% from 2024 to 2034 and reach US$ 4.6 Bn by the end of 2034

Esophageal Cancer Market Overview

Regional Outlook

Global Esophageal Cancer Market Snapshot

The burden of esophageal cancer in different age groups in Feicheng County from 2001–2012.

Yearly citation counts for the publication titled "Environmental Causes of Esophageal Cancer".

The global market for molecular diagnostics in esophageal cancer is experiencing robust growth, driven by increasing prevalence of esophageal cancer, advancements in molecular diagnostic technologies, and a rising demand for personalized medicine. The market's expansion is fueled by the critical need for early and accurate diagnosis, which significantly impacts treatment strategies and patient outcomes. Technological innovations, such as next-generation sequencing (NGS) and liquid biopsies, are offering more sensitive and specific diagnostic tools, enabling earlier detection and facilitating targeted therapies tailored to individual patient genetic profiles. This shift towards precision oncology is a primary market driver, replacing traditional methods with more effective and efficient diagnostic techniques. While challenges remain, including high testing costs and the need for skilled professionals to interpret complex results, the overall market trajectory points towards significant expansion. The increasing integration of molecular diagnostics into clinical workflows, coupled with supportive government initiatives and rising healthcare expenditure, further accelerates market growth. Furthermore, the market is segmented based on technology type (PCR, NGS, FISH, etc.), application (diagnosis, prognosis, monitoring), and end-user (hospitals, research centers, etc.). Competitive dynamics are shaped by a mix of established players and emerging companies, each vying to offer advanced technologies and comprehensive services. Geographic variations in market growth reflect disparities in healthcare infrastructure, diagnostic adoption rates, and the prevalence of esophageal cancer across different regions. North America and Europe are currently leading the market due to higher awareness, better healthcare infrastructure, and a greater adoption of advanced diagnostic technologies. However, developing economies in Asia and other regions present substantial growth opportunities due to rising healthcare investment and increased awareness of the benefits of early cancer diagnosis. The projected CAGR suggests continued substantial growth throughout the forecast period, reflecting the ongoing importance of molecular diagnostics in improving esophageal cancer management.

Technological advancements in the Esophageal Cancer industry are shaping the future market landscape. The report evaluates innovation-driven growth and how emerging technologies are transforming industry practices, offering a comprehensive outlook on future opportunities and market potential.

The global esophageal cancer drugs market is poised for substantial growth, with an estimated market size of approximately $7,800 million in 2025. This expansion is projected to be driven by a Compound Annual Growth Rate (CAGR) of around 8.5% during the forecast period of 2025-2033. This robust growth is underpinned by several key factors. The increasing incidence of esophageal cancer globally, particularly in developing regions, due to lifestyle changes, dietary habits, and rising rates of obesity and GERD, is a primary driver. Furthermore, significant advancements in drug development and the growing emphasis on targeted therapies and immunotherapies are contributing to better treatment outcomes and market expansion. The market is segmented by application, with targeted therapy expected to capture a significant share due to its personalized approach and improved efficacy. Chemotherapy remains a cornerstone, but its role is increasingly being complemented or replaced by novel agents. The market's trajectory is further shaped by evolving treatment paradigms and a greater understanding of the disease's molecular underpinnings. Key drug types like Fluorouracil, Cisplatin, Docetaxel, and Carboplatin continue to be foundational, but the pipeline is rich with innovative therapies targeting specific molecular pathways, offering new hope for patients with limited options. Restraints include the high cost of novel therapies, stringent regulatory approval processes, and the need for more extensive clinical trials. However, the growing awareness among healthcare professionals and patients about early detection and advanced treatment options, coupled with expanding healthcare infrastructure in emerging economies, will likely outweigh these challenges. Geographically, North America and Europe are expected to lead the market due to advanced healthcare systems and higher R&D investments. Asia Pacific, however, presents significant growth opportunities owing to its large patient population and increasing healthcare expenditure. This report offers an in-depth analysis of the global Esophageal Cancer Drugs market, projecting a significant Compound Annual Growth Rate (CAGR) within the Forecast Period: 2025-2033. The Base Year: 2025 serves as a pivotal point for estimation, building upon the Historical Period: 2019-2024. The Study Period: 2019-2033 encompasses both past performance and future projections, providing a holistic view of market dynamics. Our analysis will delve into key market drivers, challenges, emerging trends, and the competitive landscape, offering valuable insights for stakeholders.

Snapshot img { margin: 10px !important; } Below are some of the key findings from the esophageal cancer drugs market analysis report

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.

Get a FREE sample now!

Global Esophageal Cancer Drugs Industry Overview

Various combinations of drugs such as fluorouracil, cisplatin, docetaxel, and carboplatin are involved in standard chemotherapy regimens for the treatment of esophageal cancer. These drugs are selected based on adverse drug reactions and cancer subtypes. To ensure patient access to available therapeutics, governments in developed countries are introducing reimbursement policies. Medicare comprising of Medicare Part A (hospital insurance) and Medicare Part B (medical insurance) is a federal government program for healthcare in the US that covers chemotherapy for cancer patients. Similarly, the Ministry of Health and Long-term Care in Canada provides funds for CYRAMZA and Health Insurance Review and Assessment Service of South Korea has approved CYRAMZA for the treatment of esophageal cancer. The availability of such favorable reimbursements is one of the critical reasons that will drive esophageal cancer drugs market growth.

Additionally, the use of multimodality treatment approach will also contribute to the growth of the esophageal cancer drugs market which will register a CAGR of over 8% during the forecast period. The optimal treatment of esophageal cancer requires a combination of chemotherapy. This treatment approach aims at providing optimal treatment for esophageal cancer by combining the strengths of various treatments such as chemotherapy and targeted therapy (immunotherapy). It also combines procedures such as perioperative chemotherapy or definitive chemoradiation, radiotherapy, and surgery, which will help improve patient outcome and enhance the survival rate.

Top esophageal cancer drugs companies covered in this market research report

The esophageal cancer drugs market is fairly fragmented. By offering a complete analysis of the market’s competitive landscape and with information on the products offered by companies, this esophageal cancer drugs industry analysis report will help clients identify new growth opportunities and design innovative strategies to improve their share in the market.

The report offers a complete analysis of various companies including:

Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
Merck & Co., Inc.
Sanofi

Esophageal cancer drugs market segmentation based on geographic regions

Asia
Europe
North America
ROW

North America will account for the largest esophageal cancer drugs market share throughout the forecast period. The growth of esophageal cancer drugs market size in this region is due to major factors such as increasing incidence of esophageal cancer, availability of favorable reimbursement schemes, government initiatives, and growing awareness of esophageal cancer.

Esophageal cancer drugs market segmentation based on product

Targeted therapy
Chemotherapy

The targeted therapy market segment will account for the highest esophageal cancer drugs market share because of the increasing research on novel drugs. This involves targeting specific proteins such as the vascular endothelial growth factor (VEGF) or human epidermal growth factor receptor 2 (HER2) that contribute to cancer growth and survival.

Key highlights of the global esophageal cancer drugs market for the forecast years 2019-2023:

CAGR of the market during the forecast period 2019-2023
Detailed information on factors that will accelerate the growth of the esophageal cancer drugs market during the next five years
Precise estimation of the global esophageal cancer drugs market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the esophageal cancer drugs industry across various geographies such as Asia, Europe, North America, and ROW
A thorough analysis of the market’s competitive landscape and detailed information on several vendors
Comprehensive details on factors that will challenge the growth of esophageal cancer drugs companies 

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

Using data from the real world to solve clinical questions that cannot be answered using data from clinical trials is attracting more attention. Clinical outcomes for patients with esophageal cancer in a real-world setting might be different from data in randomized controlled trials. This study aimed to provide real world data on treatment and prognosis in Korean patients with esophageal cancer. This retrospective cancer cohort included newly diagnosed cases of esophageal cancer at 19 tertiary hospitals between January 1, 2005 and December 31, 2017. Cancer staging was defined according to the 7th edition of the American Joint Committee on Cancer criteria. We identified 6,354 patients with newly diagnosed esophageal cancer (mean age: 64.9 ± 9.0 years, 96.9% squamous cell carcinoma). The proportion of early esophageal cancer increased from 24.7% in 2005 to 37.2% in 2015 (p